[
  {
    "ts": null,
    "headline": "Jefferies Remains Bullish on Bristol-Myers Squibb Company (BMY)",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the best pharma stocks to invest in. On December 4, Jefferies reiterated a Buy rating on Bristol-Myers Squibb Company (NYSE:BMY) with a price target of $68. The same day, Scotiabank lifted the price target on Bristol-Myers Squibb Company (NYSE:BMY) to $53 from $45 while maintaining a Sector Perform rating […]",
    "url": "https://finnhub.io/api/news?id=63f7eb03b4d6c706c95cc04f8cc95538c8073d5ba1864bf9fefabea7bb3d100a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765384125,
      "headline": "Jefferies Remains Bullish on Bristol-Myers Squibb Company (BMY)",
      "id": 137750392,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the best pharma stocks to invest in. On December 4, Jefferies reiterated a Buy rating on Bristol-Myers Squibb Company (NYSE:BMY) with a price target of $68. The same day, Scotiabank lifted the price target on Bristol-Myers Squibb Company (NYSE:BMY) to $53 from $45 while maintaining a Sector Perform rating […]",
      "url": "https://finnhub.io/api/news?id=63f7eb03b4d6c706c95cc04f8cc95538c8073d5ba1864bf9fefabea7bb3d100a"
    }
  },
  {
    "ts": null,
    "headline": "2 Pharmaceutical Stocks to Buy at a Discount",
    "summary": "Investors are currently so focused on one type of drug that even good companies are being left on the sidelines.",
    "url": "https://finnhub.io/api/news?id=eafcb5a84e891732caa98815c12cd8c615616d3e47f1a39edcc06d6c5195e1aa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765380000,
      "headline": "2 Pharmaceutical Stocks to Buy at a Discount",
      "id": 137750083,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Investors are currently so focused on one type of drug that even good companies are being left on the sidelines.",
      "url": "https://finnhub.io/api/news?id=eafcb5a84e891732caa98815c12cd8c615616d3e47f1a39edcc06d6c5195e1aa"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca: A Rare Compound Growth Opportunity In Biopharma",
    "summary": "AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about AZN stock here.",
    "url": "https://finnhub.io/api/news?id=7607e031783e690b2011e6797309b77b7a7084aa1403fc9ee0fe0c21f814be29",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765362409,
      "headline": "AstraZeneca: A Rare Compound Growth Opportunity In Biopharma",
      "id": 137747724,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307043297/image_1307043297.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about AZN stock here.",
      "url": "https://finnhub.io/api/news?id=7607e031783e690b2011e6797309b77b7a7084aa1403fc9ee0fe0c21f814be29"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb (BMY): Revisiting Valuation After a Recent Share Price Rebound",
    "summary": "Bristol-Myers Squibb (BMY) has been quietly rebuilding momentum, with the stock up around 8% over the past month even as its one year return remains slightly negative. That disconnect is drawing fresh investor attention. See our latest analysis for Bristol-Myers Squibb. That recent 30 day share price return of about 8% contrasts with a negative year to date move and an 8.5% decline in one year total shareholder return, suggesting early but improving momentum as investors reassess risk and...",
    "url": "https://finnhub.io/api/news?id=b256686969024c6e2c4132a2fade45de910911d13b47f05236a13f5ba6dd6260",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765325568,
      "headline": "Bristol Myers Squibb (BMY): Revisiting Valuation After a Recent Share Price Rebound",
      "id": 137750394,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb (BMY) has been quietly rebuilding momentum, with the stock up around 8% over the past month even as its one year return remains slightly negative. That disconnect is drawing fresh investor attention. See our latest analysis for Bristol-Myers Squibb. That recent 30 day share price return of about 8% contrasts with a negative year to date move and an 8.5% decline in one year total shareholder return, suggesting early but improving momentum as investors reassess risk and...",
      "url": "https://finnhub.io/api/news?id=b256686969024c6e2c4132a2fade45de910911d13b47f05236a13f5ba6dd6260"
    }
  }
]